## As Passed by the House

# 128th General Assembly Regular Session 2009-2010

H. B. No. 384

### **Representative Bolon**

Cosponsors: Representatives Balderson, Boyd, Chandler, Daniels,
Derickson, Dolan, Domenick, Evans, Fende, Garland, Hackett, Hagan, Harris,
Harwood, Heard, Letson, Lundy, Newcomb, Pillich, Sears, Ujvagi,
Weddington, Batchelder, Belcher, Blair, Book, Boose, Brown, Burke, Carney,
Celeste, Coley, Combs, DeBose, DeGeeter, Driehaus, Dyer, Foley, Gardner,
Garrison, Gerberry, Goyal, Grossman, Hall, Hite, Hottinger, Lehner, Luckie,
Mandel, Mecklenborg, Okey, Otterman, Patten, Phillips, Pryor, Reece, Sayre,
Skindell, Slesnick, Snitchler, Stewart, Uecker, Wachtmann, Williams, B.,
Winburn, Yuko, Zehringer

#### A BILL

То	amend sections 1751.66 and 3923.60 of the Revised	1
	Code to use the compendia adopted by the United	2
	States Department of Health and Human Services to	3
	determine whether an insurer may exclude coverage	4
	for off-label drug usage.	5

#### BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF OHIO:

Section 1. That sections 1751.66 and 3923.60 of the Revised	6
Code be amended to read as follows:	7
Sec. 1751.66. (A) No individual or group health insuring	8
corporation policy, contract, or agreement that provides coverage	9
for prescription drugs shall limit or exclude coverage for any	10
drug approved by the United States food and drug administration on	11

the basis that the drug has not been approved by the United States	12
food and drug administration for the treatment of the particular	13
indication for which the drug has been prescribed, provided the	14
drug has been recognized as safe and effective for treatment of	15
that indication in one or more of the standard medical reference	16
compendia specified in division (B)(1) of this section adopted by	17
the United States department of health and human services under 42	18
<u>U.S.C. 1395x (t)(2), as amended,</u> or in medical literature that	19
meets the criteria specified in division $(B)$ of this section.	20
(B)(1) The compendia accepted for purposes of division (A) of	21
this section are the following:	22
(a) The "AMA drug evaluations," a publication of the American	23
medical association;	24
(b) The "AHFS (American hospital formulary service) drug	25
information," a publication of the American society of health	26
system pharmacists;	27
(c) "Drug information for the health care provider," a	28
publication of the United States pharmacopoeia convention.	29
(2) Medical literature may be accepted for purposes of	30
division (A) of this section only if all of the following apply:	31
$\frac{(a)}{(1)}$ Two articles from major peer-reviewed professional	32
medical journals have recognized, based on scientific or medical	33
criteria, the drug's safety and effectiveness for treatment of the	34
indication for which it has been prescribed;	35
(b)(2) No article from a major peer-reviewed professional	36
medical journal has concluded, based on scientific or medical	37
criteria, that the drug is unsafe or ineffective or that the	38
drug's safety and effectiveness cannot be determined for the	39
treatment of the indication for which it has been prescribed;	40
$\frac{(e)(3)}{(3)}$ Each article meets the uniform requirements for	41

71

manuscripts submitted to biomedical journals established by the	42	
international committee of medical journal editors or is published		
in a journal specified by the United States department of health	44	
and human services pursuant to Section 1861(t)(2)(B) of the	45	
"Social Security Act," 107 Stat. 591 (1993), 42 U.S.C. 1395	46	
(x)(t)(2)(B), as amended, as accepted peer-reviewed medical		
literature.	48	
(C) Coverage of a drug required by division (A) of this	49	
section includes medically necessary services associated with the	50	
administration of the drug.	51	
(D) Division (A) of this section shall not be construed to do	52	
any of the following:	53	
(1) Require coverage for any drug if the United States food	54	
and drug administration has determined its use to be	55	
contraindicated for the treatment of the particular indication for	56	
which the drug has been prescribed;	57	
(2) Require coverage for experimental drugs not approved for	58	
any indication by the United States food and drug administration;	59	
(3) Alter any law with regard to provisions limiting the	60	
coverage of drugs that have not been approved by the United States	61	
food and drug administration;	62	
(4) Require reimbursement or coverage for any drug not	63	
included in the drug formulary or list of covered drugs specified	64	
in a health insuring corporation contract;	65	
(5) Prohibit a health insuring corporation from limiting or	66	
excluding coverage of a drug, provided that the decision to limit	67	
or exclude coverage of the drug is not based primarily on the	68	
coverage of drugs required by this section.	69	
(E) This section applies only to health insuring corporation	70	

policies, contracts, and agreements that are described in division

medical journals have recognized, based on scientific or medical

criteria, the drug's safety and effectiveness for treatment of the

100

101

H. B. No. 384 As Passed by the House	Page 6
in a policy of sickness and accident insurance;	
(5) Prohibit a policy of sickness and accident insurance from	133
limiting or excluding coverage of a drug, provided that the	134
decision to limit or exclude coverage of the drug is not based	135
primarily on the coverage of drugs required by this section.	136
(E) This section, as amended, applies only to policies of	137
sickness and accident insurance that are described in division (A)	138
of this section and that are delivered, issued for delivery, or	139
renewed in this state on or after the effective date of this	140
amendment.	
Section 2. That existing sections 1751.66 and 3923.60 of the	142
Revised Code are hereby repealed.	